Investigation of the relationship between MMP-1 (- 1607 1G/2G), MMP-3 (- 1171 5A/6A) gene variations and development of bladder cancer
- PMID: 34693500
- DOI: 10.1007/s11033-021-06775-2
Investigation of the relationship between MMP-1 (- 1607 1G/2G), MMP-3 (- 1171 5A/6A) gene variations and development of bladder cancer
Abstract
Background: Chronic inflammation is an important risk factor in the development of bladder cancer. It may stimulate growth and metastasis of cancer cells. The inflammatory process includes MMP activities and expression. MMP activation can be stimulated by various inflammatory cells. Pathological processes such as bladder cancer may occur due to imbalance in MMP activities. In our study, we aimed to determine the relationship between MMP-1, MMP-3 gene variations associated with chronic inflammation and the bladder cancer development.
Methods: Our study was carried out with 89 bladder cancer patients and 78 healthy controls. PCR-RFLP methods were applied to determine MMP-1 and MMP-3 gene variations genotype distributions.
Results: 1G/1G homozygous and 1G/2G heterozygous genotypes of MMP-1 gene variation were determined more in patients than controls. The 5A/5A homozygous and 5A/6A heterozygous genotypes of the MMP-3 gene variation were detected more in patients than controls. The significant difference was detected in terms of genotype distributions of MMP-1 and MMP-3 gene variations between these groups (p < 0.05). In addition to, the most common haplotype in the patient group were detected as 1G/2G-5A/6A (20.22%).
Conclusion: In this study, MMP-1 and MMP-3 gene variations were determined as possible genetic risk factors for bladder cancer development in the Thrace population.
Keywords: Bladder cancer; Chronic inflammation; MMP-1 gene variation; MMP-3 gene variation; PCR–RFLP.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
References
-
- Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D (2021) Advances in bladder cancer biology and therapy. Nat Rev Cancer 21(2):104–121. https://doi.org/10.1038/s41568-020-00313-1 - DOI - PubMed
-
- Cao Y, Tian T, Li W, Xu H, Zhan C, Wu X, Wang C et al (2020) Long non-coding RNA in bladder cancer. Clin Chim Acta 503:113–121. https://doi.org/10.1016/j.cca.2020.01.008 - DOI - PubMed
-
- Cai Z, Liu Q (2021) Understanding the Global Cancer Statistics 2018: implications for cancer control. Sci China Life Sci 64(6):1017–1020. https://doi.org/10.1007/s11427-019-9816-1 - DOI - PubMed
-
- Li Y, Sun L, Guo X, Mo N, Zhang J, Li C (2021) Frontiers in bladder cancer genomic research. Front Oncol 20(11):670729. https://doi.org/10.3389/fonc.2021.670729 - DOI
-
- Liao CH, Tsai CW, Chang WS, Wang ZH, Gong CL, Wu HC, Wang BR et al (2021) Association of matrix metalloproteinase-1 genotypes with bladder cancer risk. In Vivo 35(5):2535–2540. https://doi.org/10.21873/invivo.12535 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
